Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $691.11 million. The enterprise value is $913.37 million.
| Market Cap | 691.11M |
| Enterprise Value | 913.37M |
Important Dates
The last earnings date was Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 62.83 million shares outstanding. The number of shares has decreased by -0.79% in one year.
| Shares Outstanding | 62.83M |
| Shares Change (YoY) | -0.79% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 51.09% |
| Owned by Institutions (%) | 31.52% |
| Float | 26.25M |
Valuation Ratios
The trailing PE ratio is 278.25 and the forward PE ratio is 10.08.
| PE Ratio | 278.25 |
| Forward PE | 10.08 |
| PS Ratio | 1.56 |
| Forward PS | 1.30 |
| PB Ratio | 2.21 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 297.86 |
| EV / Sales | 2.07 |
| EV / EBITDA | 16.01 |
| EV / EBIT | 24.06 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.81.
| Current Ratio | 1.22 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | 4.47 |
| Debt / FCF | n/a |
| Interest Coverage | 1.32 |
Financial Efficiency
Return on equity (ROE) is 1.00% and return on invested capital (ROIC) is 2.09%.
| Return on Equity (ROE) | 1.00% |
| Return on Assets (ROA) | 0.40% |
| Return on Capital (ROIC) | 2.09% |
| Revenue Per Employee | $1.10M |
| Profits Per Employee | $7,666 |
| Employee Count | 400 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.90 |
Taxes
In the past 12 months, BIOX has paid $6.23 million in taxes.
| Income Tax | 6.23M |
| Effective Tax Rate | 67.01% |
Stock Price Statistics
The stock price has decreased by -18.64% in the last 52 weeks. The beta is 0.56, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -18.64% |
| 50-Day Moving Average | 11.41 |
| 200-Day Moving Average | 12.11 |
| Relative Strength Index (RSI) | 48.80 |
| Average Volume (20 Days) | 49,241 |
Short Selling Information
| Short Interest | 346,667 |
| Short Previous Month | 333,564 |
| Short % of Shares Out | 0.55% |
| Short % of Float | 1.32% |
| Short Ratio (days to cover) | 4.47 |
Income Statement
In the last 12 months, BIOX had revenue of $441.98 million and earned $3.07 million in profits. Earnings per share was $0.04.
| Revenue | 441.98M |
| Gross Profit | 175.81M |
| Operating Income | 36.04M |
| Pretax Income | 9.30M |
| Net Income | 3.07M |
| EBITDA | 57.06M |
| EBIT | 37.96M |
| Earnings Per Share (EPS) | $0.04 |
Balance Sheet
The company has $32.81 million in cash and $255.08 million in debt, giving a net cash position of -$222.26 million or -$3.54 per share.
| Cash & Cash Equivalents | 32.81M |
| Total Debt | 255.08M |
| Net Cash | -222.26M |
| Net Cash Per Share | -$3.54 |
| Equity (Book Value) | 313.35M |
| Book Value Per Share | 4.99 |
| Working Capital | 74.21M |
Cash Flow
In the last 12 months, operating cash flow was $9.97 million and capital expenditures -$21.76 million, giving a free cash flow of -$11.79 million.
| Operating Cash Flow | 9.97M |
| Capital Expenditures | -21.76M |
| Free Cash Flow | -11.79M |
| FCF Per Share | -$0.19 |
Margins
Gross margin is 39.78%, with operating and profit margins of 8.15% and 0.69%.
| Gross Margin | 39.78% |
| Operating Margin | 8.15% |
| Pretax Margin | 2.10% |
| Profit Margin | 0.69% |
| EBITDA Margin | 12.91% |
| EBIT Margin | 8.59% |
| FCF Margin | -2.67% |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.79% |
| Shareholder Yield | 0.79% |
| Earnings Yield | 0.44% |
| FCF Yield | -1.71% |
Analyst Forecast
The average price target for BIOX is $20.33, which is 84.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.33 |
| Price Target Difference | 84.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 19.56% |
| EPS Growth Forecast (5Y) | 44.40% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |